ICD-10 Coding for Drug-Induced Parkinsonism(G21.1, G21.11, G21.11B)
Learn about ICD-10 coding for drug-induced parkinsonism, including G21.19 and G21.11 codes, documentation requirements, and clinical validation.
Complete code families applicable to Drug-Induced Parkinsonism
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| G21.19 | Other drug-induced secondary parkinsonism | Use when parkinsonism is caused by drugs other than neuroleptics, such as metoclopramide or valproate. |
|
| G21.11 | Neuroleptic-induced parkinsonism | Use when parkinsonism is caused by neuroleptic drugs. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutDrug-Induced Parkinsonism
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Drug-Induced Parkinsonism.
Vague documentation of drug-induced parkinsonism
Impact
Clinical: May lead to inappropriate treatment decisions., Regulatory: Increases risk of audit findings., Financial: Potential for denied claims due to insufficient documentation.
Mitigation
Ensure detailed drug history is recorded., Specify symptom onset and resolution.
Confusing drug-induced parkinsonism with Parkinson's disease
Impact
Reimbursement: Incorrect coding may lead to improper DRG assignment and reimbursement., Compliance: Misclassification can result in compliance issues during audits., Data Quality: Affects the accuracy of clinical data and patient records.
Mitigation
Use G21.11 or G21.19 with appropriate T-code for drug causality.
Documentation of drug causality
Impact
Failure to document drug causality can lead to audit issues.
Mitigation
Ensure all records include specific drug names and symptom timelines.